Nuclear CYLD expression plays a role in HCC therapy response in vitro

The deubiquitinase CYLD removes K63-linked ubiquitin chains from molecules involved, e.g., in NF-kB, Wnt/ß-catenin and BCL-3 signaling pathways. CYLD is dysregulated in different cancers, including hepatocellular carcinoma (HCC). Loss of CYLD is characterized by enhanced NF-κB-signaling and increased cell survival. In previous studies, we demonstrated decreased levels of CYLD expression in human HCC. In recent analysis of CYLD expression in tissue microarrays, survival analysis of HCC patients after resection revealed a more favorable outcome of patients with positive nuclear CYLD expression. We hypothesize that…